| Name | Title | Contact Details |
|---|---|---|
Kevin Hsiao |
Information Security Officer | Profile |
Oakbridge Insurance is a prominent independent insurance and risk management agency with over 100 years of experience. Founded with a mission to enhance the insurance industry through community-focused service, Oakbridge combines the flexibility of an independent agency with the resources of a larger brokerage. As of 2023, it operates under Audax Private Equity, providing a range of commercial and personal insurance solutions. The company specializes in commercial property and casualty insurance, employee benefits, surety bonds, personal property and casualty insurance, and risk management services. Oakbridge operates through a partnership model, having expanded from four founding agencies to 13 partner firms by 2022, employing 280 people. The agency fosters a collaborative culture, emphasizing trust and long-term relationships with clients. In 2022, Oakbridge was recognized as a Top 100 Property/Casualty Agency by *Insurance Journal*, highlighting its strong position in the industry.
Forever North Partners (FNP) is a purpose-driven company partnering with high-achieving businesses poised for the next phase of growth. Focused on companies possessing unique, disruptive technologies or services, FNP is dedicated to facilitating your ascent to new heights. FNP services offerings: Investees and Investors: FNP excels in collaborating with dynamic, forward-thinking companies seeking additional investment capital to fuel their growth ambitions. Leveraging its extensive network, FNP identifies investors whose interests align with your companies potential. Operational Excellence Services: Boasting over a century of collective industry experience, FNP applies its proven Market-Driven Application Approach to craft precise positioning and messaging strategies empowering your company to penetrate competitive markets, secure new customers, and drive sales. FNP crafts targeted sales and marketing campaigns complete with compelling collateral, ensuring effective outreach to high-value customers within specific application spaces. FNPs network of key opinion leaders (KOLs) will amplify your corporate messaging to drive top-line growth. Executive Recruiting: FNP understands that success hinges on having the right people in pivotal roles. While adopting the necessary tools for growth is crucial, it is the people who epitomize your values and culture that truly propel your company forward. Leadership, especially, demands exceptional individuals who embody your vision and are committed to realizing your companys mission. FNP has earned a stellar reputation for identifying and securing high-caliber, high-performance executives capable of translating your vision into reality. Regulatory Affairs: Navigating the intricate landscape of the life sciences market demands a profound understanding of ever-changing regulatory compliance issues. Reach regulatory excellence with FNP - Your Trusted Life Sciences Partner. Let FNP guide you on your journey to success.
Atosa is a major manufacturer of commercial kitchen equipment, with a breadth of offering including refrigeration, cooking equipment, warming/holding equipment, stainless steel fabrication equipment, and much more. Atosas world-class manufacturing facilities and highly skilled employees, combined with innovative manufacturing procedures ensure that our customers always receive top-quality products at economical prices.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.